Mirvetuximab Soravtansine — Drug Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

7 Recruiting

3 Completed trials

7 Sponsors

18 Countries

Phase III

Phase II

Phase III/IV

Phase IV

Phase III: 3 Phase II: 5 Phase III/IV: 1 Phase IV: 1

Indications tested

Ovarian epithelial cancer 5 Fallopian tube cancer 5 Ovarian cancer recurrent 2 Ovarian cancer 2 Breast cancer 1 Fallopian tube cancer metastatic 1 Breast cancer metastatic 1 Ovarian cancer metastatic 1 Breast cancer female 1

Sponsors using this IMP

AbbVie Deutschland GmbH & Co. KG 5 AGO Research GmbH 1 AstraZeneca AB 1 Champalimaud Clinical Centre 1 Eli Lilly & Co. 1 Immunogen Inc. 1 Rita Fior 1

All trials

10 total

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B… Recruiting

2025-522255-25-00 Phase III 15 countries Eli Lilly & Co.
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting

2025-520466-22-00 Phase III 10 countries AstraZeneca AB
Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s… Recruiting

2022-501606-35-01 Phase III/IV 11 countries AbbVie Deutschland GmbH & Co. KG
Evaluation of epithelial ovarian, primary peritoneal, or fallopian tube cancer treatment in first recurrance using platinum-based chemothera… Recruiting

2022-501220-14-00 Phase II 3 countries AbbVie Deutschland GmbH & Co. KG
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Intravenous Mirvetuximab Soravtansin… Recruiting

2025-521606-18-00 Phase II 5 countries AbbVie Deutschland GmbH & Co. KG
A study to evaluate dosing schedules of mirvetuximab soravtansine in patients with epithelial ovarian, primary peritoneal, or fallopian tube… Recruiting

2024-517184-23-00 Phase II 4 countries AbbVie Deutschland GmbH & Co. KG
zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric ra… Recruiting

2023-509598-22-01 Phase IV 1 country Champalimaud Clinical Centre; Rita Fior
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Rec… Ended

2023-505617-24-00 Phase II 4 countries AbbVie Deutschland GmbH & Co. KG
A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible fo… Ended

2024-516959-40-00 Phase II 1 country AGO Research GmbH
A study to test Mirvetuximab Soravtansine (IMGN853) aganist doctor's choice of cancer medicines in women with advanced Epithelial Ovarian, P… Ended

2024-516111-25-00 Phase III 1 country Immunogen Inc.

Showing 1–10 of 10 trials

← All drugs A–Z